Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells

Shinpei Nishimura1, Shunsuke Takahashi, Hiromi Kamikatahira

  • 1Department of Molecular Cell Function, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Ohe-honmachi, Kumamoto 862-0973, Japan.

Insights

Researchers identified a novel peptide, CAYHRLRRC, that selectively targets leukemia and lymphoma cells via macropinocytosis. This peptide shows promise for developing targeted therapies against these blood cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Ligand-directed delivery offers potential for novel leukemia and lymphoma therapies.
  • Targeting cellular pathways like macropinocytosis is a key strategy in drug development.

Purpose of the Study:

  • To identify and characterize a novel ligand for targeting leukemia and lymphoma cells.
  • To explore the potential of this ligand for developing targeted anti-cancer therapies.

Main Methods:

  • Phage-display screening of acute T-lymphoblastic leukemia Molt-4 cells to isolate targeting peptides.
  • Flow cytometry and endocytosis inhibition assays to confirm cellular uptake mechanism (macropinocytosis).
  • Evaluation of peptidomimetics derived from the identified peptide for selective cell death induction.

Main Results:

  • A peptide, CAYHRLRRC, was isolated with high binding affinity for leukemia/lymphoma cells and patient samples.
  • CAYHRLRRC is internalized via energy- and temperature-dependent macropinocytosis in leukemia cell lines.
  • CAYHRLRRC-directed peptidomimetics induced selective cell death in leukemia and lymphoma cells, unlike a control peptidomimetic.

Conclusions:

  • The peptide CAYHRLRRC is selectively internalized by leukemia and lymphoma cells through macropinocytosis.
  • CAYHRLRRC represents a promising drug lead for developing ligand-directed therapies against leukemia and lymphoma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...